Health · Pharma & Biotech · 1 hr ago
Usona’s reported psilocybin filing reshapes forecasts for Compass drug
Usona Institute may have filed for FDA approval of its psilocybin treatment for major depressive disorder, though the Wisconsin nonprofit has not confirmed the submission.
Usona began a Phase 3 trial in 2024 and received an FDA voucher for faster review, but it has not publicly released the trial results.
Compass Pathways has completed its application for COMP360, a psilocybin treatment for treatment-resistant depression.
The two drugs target different forms of depression, and Usona says its mission is to provide psilocybin at low cost, while Compass is expected to price its patented drug like a branded medicine.
Analysts still see blockbuster potential for COMP360, with one estimate putting peak sales at $1.9 billion in treatment-resistant depression alone.
The reported Usona filing unsettled investors, and Compass shares fell around 30% after the news before the company announced its application was complete.
Payer coverage and patient access remain key hurdles for Compass, while the FDA’s decisions on both applications could shape how the market develops.
Reports that Usona Institute filed for FDA approval of its psilocybin drug have unsettled forecasts for Compass Pathways’ COMP360.
Usona has not confirmed the reported filing, and the institute said it was not commenting.
Compass shares fell around 30% after the reports, then the company said a week later that it had completed its own approval application.
Analysts still forecast that COMP360 could become a blockbuster, while saying the market may have room for multiple psychedelic drugs.
Usona is studying its candidate for major depressive disorder, while Compass is developing COMP360 for treatment-resistant depression.
- Who
- Usona Institute, Compass Pathways and analysts assessing the market for psychedelic drugs.
- What
- Reports that Usona filed for FDA approval of its psilocybin candidate PSIL201 have reshaped forecasts for Compass’s COMP360. Usona has not confirmed the filing.
- When
- The report of Usona’s filing emerged earlier in November 2026; Compass announced its application was complete a week later.
- Where
- The United States; Usona is based in Wisconsin.
- Why
- The reported filing raised the possibility that Usona could become a competitor to Compass in the psychedelic drug market.
This story does not have two clearly opposing sides.
Usona launched its phase 3 trial of PSIL201.
The FDA said Usona’s treatment had secured a voucher for speedier review under the Commissioner’s National Priority Voucher Program.
An industry analyst reported that Usona had filed for FDA approval, a filing Usona did not confirm.
Compass announced it had completed its own approval application.
- Usona candidate
- PSIL201, an investigational psilocybin treatment
- Usona trial
- Phase 3 trial launched in March 2024
- FDA voucher
- Usona’s treatment secured a speedier-review voucher in April 2026
- Compass candidate
- COMP360, for treatment-resistant depression
- Compass share move
- Shares dropped around 30% following reports of Usona’s filing
- COMP360 forecast
- RBC Capital Markets analysts projected peak sales of $1.9 billion in treatment-resistant depression
What people are saying
caught many investors by surprise
sufficient room for many new psychedelics